$599

Why A Lexicon Deal for Sota Feels Like Momentum Is Building

Following the EMPEROR-Preserved and FIGARO-DKD data readouts at ESC 2021, it seems as if a deal for Lexicon’s sotagliflozin should be building momentum. Below, FENIX provides thoughts on the quickly evolving HF/CKD market and insight into what a potential deal for sotagliflozin may look like, despite some caveats.

This content is for Read Less members only.
Register
Already a member? Log in here